TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02962050

Intervention type: PROCEDURE
Intervention: Videofluoroscopic Swallowing Study (VFSS)
Description: Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing

Intervention type: DEVICE
Intervention: Voluntary Peak Cough Flow Testing
Description: Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.

Intervention type: DEVICE
Intervention: Iowa Oral Performance Instrument
Description: The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.

Intervention type: DRUG
Intervention: Capsaicin Challenge
Description: A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.

Intervention type: DEVICE
Intervention: Pulmonary Function Testing
Description: Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.

Intervention type: OTHER
Intervention: Eating Assessment Tool 10
Description: The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.

Intervention type: OTHER
Intervention: The Center for Neurologic Study Bulbar Function Scale
Description: The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
Study: NCT00488384

Intervention type: DRUG
Group type: OTHER
Intervention: Chemopreventive application (Acitretin)
Description: Chemopreventive application (Acitretin)
Study: NCT02007174

Intervention type: DRUG
Intervention: Bevacizumab

Intervention type: DRUG
Intervention: Medical Treatment
Description: Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.

Intervention type: DRUG
Intervention: Medical Treatment
Description: Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.

Intervention type: PROCEDURE
Intervention: Argon laser treatment
Study: NCT03345472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation System
Description: Implanted neurostimulation system (neurostimulator and leads) with high dose stimulation parameters.
Study: NCT02481973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Homoeopathic Remedy
Description: Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
Study: NCT01399580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
Study: NCT02148237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants in this condition will receive usual WIC care in addition to Contingency Management (CM). BF will be determined by direct observation.
Study: NCT03516760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEM333
Description: infusion of GEM333; administered intravenously and continuously over 10 days
Study: NCT02925130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute oral intake of a placebo drug
Study: NCT04136431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programed cryotherapy and continuous passive motion
Description: The intervention group started to use a CPM machine and applied programed cryotherapy intermittently within one hour while returning to the ward on the day of surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unrogramed cryotherapy and continuous passive motion
Description: A CPM machine and cryotherapy were not applied on the day of surgery while returning to the ward
Study: NCT02870855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrauterine injection of HCG
Description: intrauterine injection of HCG berore blastocyst transfer
Study: NCT02330848

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Walnut Calorie controlled
Description: The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
Study: NCT02400957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver nanoparticles
Description: Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
Study: NCT01572948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: roflumilast
Description: The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
Study: NCT04025203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arginine
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: oral capsules
Study: NCT02067364

Intervention type: DEVICE
Group type: OTHER
Intervention: Fit & Function test
Study: NCT05134961

Intervention type: PROCEDURE
Intervention: Pancreaduodenectomy and possible adjuvant therapy
Description: Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.
Study: NCT03527563

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet Medical Model
Description: Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
Study: NCT02105532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive transfusion policy
Description: Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Transfusion Policy
Description: Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
Study: NCT01936532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~* Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~* Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT02127190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10 emulsion
Description: CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02646527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
Study: NCT00353418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: 180 µg subcutaneously weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 µg subcutaneously weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800 mg orally daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000 mg or 1200 mg (based on patient weight of \< 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
Study: NCT01225679

Intervention type: DEVICE
Intervention: positive airway pressure, Non-invasive mechanic ventilation
Description: Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.~Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O.
Study: NCT01576692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized anti-GD2 antibody
Description: A maximum of 6 courses of therapy may be given on the following schedule:~* Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy~* Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)~* Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m\^2)/dose, over 4 hours daily~* NK Cell dosage: minimum of 0.1 \* 10\^6 cells/kg; maximum of 400 \* 10\^6 CD45+ cells/kg, given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy may include the following at the dosages shown below:~* cyclophosphamide: 400 mg/m\^2 IV days 1-5~* topotecan: 1.2 mg/m\^2 IV days 1-5~* temozolomide: 150 mg/m\^2 PO at least 1 hour before irinotecan~* irinotecan: 50 mg/m\^2 IV over 1 hour daily for 5 days~* carboplatin (AUC 8-dosing based on GFR), IV day 1 only~* ifosfamide: 2 g/m2 IV days 1-3~* etoposide: 100 mg/m2 days 1-3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytokines
Description: Cytokines may be given at the following dosages:~* interleukin-2: 1 million units/m\^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses~* GM-CSF: 250 mcg/m\^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC \>2,000/mm\^3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cells
Description: NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy \& Procedure Manual.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study: NCT00754910

Intervention type: DRUG
Intervention: porfimer sodium
Description: Given IV

Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: Patients undergo bronchoscopy
Study: NCT04743947

Intervention type: OTHER
Intervention: No intervention; observational study
Description: no intervention

Intervention type: OTHER
Intervention: No intervention; observational study
Description: no intervention

Intervention type: OTHER
Intervention: No intervention; observational study
Description: no intervention
Study: NCT03602079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A166
Description: A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A166
Description: A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A166
Description: A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A166
Description: A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A166
Description: A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
Study: NCT00091715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 6 months followed by an open-label period
Study: NCT02096341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly
Study: NCT01216436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with RNA-transfected mature autologous DC
Description: Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with RNA-transfected mature autologous DC
Description: Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with RNA-transfected mature autologous DC
Description: Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with RNA-transfected mature autologous DC
Description: Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
Study: NCT01028807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early feeding
Description: after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 day fasting
Description: Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
Study: NCT01179958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: 24 weeks of aerobic training, 4X/week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: stretching/toning
Description: stretches and toning exercises designed to promote flexibility and improved core strength
Study: NCT04668859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylcellulose
Description: Placebo will consist of inert methylcellulose
Study: NCT03021642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib test (Treatment Period 1)
Description: Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 1 (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib reference (Treatment Period 2)
Description: Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 2 (Day 22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib reference (Treatment Period 1)
Description: Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 1 (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib test (Treatment Period 2)
Description: Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 2 (Day 22)
Study: NCT03025958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Concomitant nimotuzumab was given weekly at a dose of 200 mg from one week before the start of IMRT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Briefly, the dose prescribed was 70.4 Gy, 70.4 Gy, 60.8 Gy, and 54.4 Gy in 32 fractions delivered over 6 weeks at the periphery of the planning target volume (PTV)nx+rn, PTVnd, PTV1, and PTV2, respectively, using the simultaneous integrated boost technique.
Study: NCT02916940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprophos
Description: Single subcutaneous injection of Diprophos, in the acute phase.